Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS. METHODS: -mutated PDAC. RESULTS: G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. CONCLUSIONS: -mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RMC-6236 is a RAS(ON) multi-selective inhibitor designed to target active GTP-bound RAS proteins across multiple KRAS mutant alleles.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [58]
Citations
Cites
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citation
Research works printed but not linked: 1
- Ying H, Kimmelman AC, Bardeesy N, Kalluri R, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2025;39:36-63.39510840
Cited by
Items 101–122 of 122
Gaur, K. S., Hall, W. A., Kamgar, M., McFall, T. B., Evans, D. B., & Seo, Y. D. (2026) · Cancers · doi:10.3390/cancers18203376
“Among the 26 patients with RAS G12-mutant disease treated in the second line at the 300 mg dose, the objective response rate was 35% (95% CI 17–56), median progression-free survival was 8.5 months, and median overall survival was 13.1 months [83].”
InfluentialMeng, F., Fernandez, A., Luan, C., Attiyeh, M. A., Feng, Q., Lee, A., Feng, H., Li, T., Zhou, T., Li, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.19.760262
Turabi, K. S., Sardarni, U. K., Ankenbauer, K. E., Torbit, S. M., Taranto, C. P., Dash, S., Meade, A., Cephas, A., Klute, K. A., di Magliano, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760559
Hamidi, A. A., Moaven, O., Mahmoudian, R. A., & Abbaszadegan, M. R. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00849-2
“In a phase 1/2 study of previously treated RAS-mutated PDAC, daraxonrasib produced antitumor activity and 300 mg once daily was selected for phase 3 development [31].”
InfluentialBildik, G., Yang, H., Mao, W., Gannaban, R. B., Bhardwaj, V. K., Uddin, M. N., Jung, S.-Y., Pierobon, M., Gomeiz, A., Gorfe, A. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.760748
Rat sarcoma inhibitors in and beyond gynecologic malignancies
Dwabe, S., Samaeekia, R., & Cristea, M. C. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001158
Anticancer drug discovery: Embracing the next wave of innovation
Huang, M., Geng, M., & Ding, J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01964-w
“Daraxonrasib was approved by the U.S. Food and Drug Administration in August 2026 for metastatic pancreatic adenocarcinoma with RAS mutations, a potential new standard of care in this historically dif fi cult-to-treat disease [18].”
Zheng, J., Chi, L., & Guo, Y. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101503
Rethinking therapeutic durability in cancer
van der Horst, E. H. (2026) · Oncogene · doi:10.1038/s41388-026-04036-9
Beyond BRAF V600: emerging MAPK-targeted therapeutic strategies
Gonzalez-Cao, M., Manzano, J. L., Puértolas, T., Gonzales, J., & Rosell, R. (2026) · Annals of Translational Medicine · doi:10.21037/atm-2026-0157
Fatima, F., Javed, M. A., Mirza, A., Ahmad, S., Shahzad, Z., & Murad, A. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001387
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Abdelhakeem, A. A. F., Ganatra, N., Gul, K., Saxena, H., Mohammed, N., Ashraf, A., Jones, J. C., Carr, R., Bekaii‐Saab, T., Borad, M. J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01863-x
“Resuming at the same dose after the initial Grade 2/3 event, but one dose level lower for Grade 3 diarrhea [63].”
InfluentialAdaptive Rewiring of Nucleotide Metabolism in Therapeutic Resistance
Dayanc, B., Xu, G., Zhou, X., Chen, J., Mueller, N., Kaur, H., Pham, B., Yoda, S., & Schneider, J. L. (2026) · Cancers · doi:10.3390/cancers18213498
Kocher, F., & Petzer, V. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01138-8
Nichtkleinzelliges Lungenkarzinom mit molekularer Alteration: Update zu neuen Therapien
Kemper, M., & Michels, S. Y. F. (2026) · Die Onkologie · doi:10.1007/s00761-026-02050-w
Synergizing Against RAS: The Evolving Landscape of Targeted Combinations in Pancreatic Cancer
Ghosh, A. K., Jazieh, K., Xie, H., Parish, M. A., Babiker, H. M., Bekaii‐Saab, T., Goenka, A. H., Knutson, K. L., Pandey, A., Fernández-Zapico, M. E., et al. (2026) · Cancers · doi:10.3390/cancers18213519
Bertalmio, N., Marino, F. A. L., Brundu, S., Rustichelli, S., & Giraudo, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219788
Minimal residual disease testing in gastrointestinal cancers: a US perspective
Ramaker, R. C., & Strickler, J. H. (2026) · Gastroenterology report · doi:10.1093/gastro/goag111
Molecular glues: from mechanistic insights to rational design in a new era of targeted therapy
Zheng, X., Cao, Y., Sun, S., Min, J., Qian, J., Li, N., Yang, Y., & Gu, C. (2026) · Targetome · doi:10.48130/targetome-0026-0054
Ras signaling in cancer: From molecular mechanisms to next-generation therapeutic inhibitors
Hossain, J., Choudhury, D., Bhattacharyya, S., Vedeshachaitanya, B., & Malakar, P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189751
The RAS revolution in gastrointestinal cancers: Where we are and where we go next
Cordani, M., Korc, M., & Li, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218963
Hur, J., George, S., Mukherjee, S., & Hatoum, H. A. (2026) · Cancers · doi:10.3390/cancers18223616
Metadata
- Authors
- Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., Azad, N. S., Hecht, J. R., Ou, S. H. I., Lin, T., Kar, S., Tao, L., Vora, R., Hegde, A., Aung, K., & Hong, D. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- NEXT Oncology Virgina, Virgina Cancer Specialists Research Institute, Fairfax
- Christ Hospital (US)
- NEXT Oncology, San Antonio, TX
- NYU Langone Health (US)
- Mary Crowley Cancer Research Center (US)
- Sarah Cannon Research Institute, Nashville
- Columbia University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of California, Los Angeles (US)
- University of California, Irvine (US)
- Revolution Medicines (United States) (US)
- Miami Cancer Institute, Miami
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-05-07
- Volume
- 394
- Issue
- 18
- Pages
- 1790-1802
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W7160408317
- Cited by
- 90
- References
- 35
- Citations by year
- 2026: 89
- FWCI
- 263.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Revolution Medicines
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- daraxonrasib, RMC-6236, objective response rate, progression-free survival, overall survival
- MeSH terms
- Progression-Free Survival, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Pancreatic Neoplasms, Piperazines, Genes, ras, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.